11/17/2016 10:36:23 AM
? Partnership combines Horizon’s HDx™ Reference Standards with Sophia Genetics’ artificial intelligence
? The use of Horizon’s Reference Standards will improve the quality of molecular profiling by SOPHiA™ artificial intelligence in oncology patient samples
? Users of the Sophia DDM® analytical platform will immediately benefit from the partnership to closely monitor the performance of their genomic tests
LAUSANNE, Switzerland and Cambridge, UK – 17 November 2016: Sophia Genetics, the global leader in Data-Driven Medicine, and Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world-leader in the application of gene editing technologies, today announced they have entered into a new partnership to improve the quality of Next Generation Sequencing (NGS) based genetic testing in oncology patient samples.
Under the terms of the agreement, Horizon’s HDx™ Reference Standards will be combined with Sophia Genetics’ artificial intelligence, providing hospitals and laboratories with more accurate and high quality NGS testing services, assays and genomic data analysis.
In particular, current and future users of the Sophia DDM® analytical platform will be able to assess the quality of their NGS assays, reaching the highest levels of sensitivity and specificity. The use of HDx Reference Standards will help with performance monitoring as well as reproducibility and repeatability of NGS tests.
Jurgi Camblong, Chief Executive Officer and co-founder, Sophia Genetics, commented: “The quality of molecular profiling is a cornerstone of NGS testing and relies on a series of technical steps being performed correctly, from the collection of patient samples and DNA extraction, to creating and analysing genomic data. Sophia Genetics helps hospitals and laboratories to make the most of their NGS testing and we are delighted to combine Horizon’s Reference Standards with our artificial intelligence for Data-Driven Medicine, increasing the number of patients that will benefit from reliable NGS genomic testing results.”
Dr. Darrin M. Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Our new partnership with Sophia Genetics demonstrates the increasingly important role well validated controls have in the provision of molecular assays, especially for complex technologies such as NGS as they become more widely adopted. We look forward to working closely with Sophia Genetics as our Reference Standards become an important component of their workflows.”
Financial terms for the partnership have not been disclosed.
Notes to editors:
About NGS Reference Standards
Routine diagnostics call for the highest levels of sensitivity and specificity. The use of Horizon’s HDx Reference Standards provides important insight into assay performance and limitations, monitoring of reproducibility, and insight into the quality of patient samples used as inputs into a workflow. By controlling for these potential sources of variability, the quality of data generated by NGS can be substantially improved.
For further information from Sophia Genetics, please contact:
Weber Shandwick Switzerland
+41 79 127 63 58
About Sophia Genetics
Sophia Genetics, the global leader in Data-Driven Medicine, brings together expertise in genomics, bioinformatics, machine-learning and data privacy. Based in Switzerland, the company is known for its medical standards and Swiss precision, accuracy and quality management. It offers health professionals performing clinical genomic testing: bioinformatics analysis, quality assurance and genomics data secure banking. Sophia Genetics does not hold personal information, and the data the company holds is anonymised. Developed by the company, SOPHiA™, the world’s most advanced and used artificial intelligence for Data-Driven Medicine, helps laboratories reduce the cost, overcome complexity and fulfil quality constraints related to clinical genomics. For more information, please visit http://www.sophiagenetics.com/ @SophiaGenetics / @JurgiCamblong.
comments powered by